In March 2011, a medical officer working in a metropolitan New South Wales (NSW) neonatal intensive care unit (NICU) was diagnosed with active pulmonary tuberculosis (TB). He had immigrated to Australia from a high-incidence country 2 years earlier with negative pre-immigration screening. Occupational TB screening prior to commencing employment at the hospital, conducted in line with NSW Health policy, 1 was also negative. The man was screened again, also in line with the NSW Health policy, after he displayed TB symptoms (i.e. a 6-month history of nonproductive cough and weight loss), and was smear-positive on induced sputum. Mycobacterium tuberculosis was confirmed on polymerase chain reaction, fully sensitive to standard anti-TB therapy.
The index case worked full-time in the NICU during his infectious period from December 2010 to March 2011. As neonates are at higher risk than older children or adults of developing severe and potentially fatal disease soon after infection with TB, it was decided to immediately offer screening to all exposed neonates and others who were potentially exposed rather than implementing a staged response. 2, 3 The outcome of this investigation is being reported elsewhere. 4 Here we describe the costs of the investigation.
Contact investigation
All 125 neonates, 165 of their relatives and 122 health care workers identified from medical records and departmental rosters as having had contact with the index case during his infectious period were offered screening (Table 1) .
Ninety-six neonates were followed up at the hospital, 15 were followed up in other Local Health Districts, nine had died of unrelated causes and five failed to attend. Exposed neonates received a tuberculin skin test (TST) at 3 months corrected age; TSTs have been shown to be unreliable prior to this age. [5] [6] [7] Neonates who were too young to be screened were commenced on isoniazid prophylaxis until they reached 3 months corrected age.
Relatives and health care workers were offered TST screening at the Chest Clinic. A reaction of $10 mm (or $15 mm with a Bacille Calmette-Guérin (BCG) scar) was defined as a positive TST.
Data on exposure and outcomes were collected from clinical records and departmental rosters. None of the 100 neonates screened (89 in the hospital and 11 in other Local Health Districts) had positive TSTs. 4 Fifty-one of 152 (34%) relatives and nine of 120 (8%) health care workers screened had positive TSTs. 4 All subsequently had negative chest X-rays, sputum cultures and/or interferongamma release assays (IGRAs). All positive TSTs were associated with origin from a high-incidence country and/ or previous BCG vaccination. No adult contacts were treated for TB infection or disease.
Resources used
The time spent on this investigation by nurses, doctors and pharmacists was obtained from rosters and interviews with staff. Salaries were calculated using 2011 NSW Health awards. [8] [9] [10] Travel costs were estimated using National Roads and Motorists' Association costs for a mediumsized vehicle. 11 The costs of laboratory tests and radiology were obtained from the Medicare Benefits Schedule (items 58503 and 69327), and hospital radiology and pathology departments. 12 The hospital pharmacy provided information on the cost of isoniazid. The cost of consumables was calculated from clinic invoices. Car parking and postage costs were obtained from the investigation cost centre. All costs presented are therefore estimates (Table 2 ).
Neonates were screened by Chest Clinic registered nurses. Neonates on isoniazid were also monitored in medical review clinics. Chest Clinic and infection control clinical nurse consultants also attended the neonatal clinics. The time nurses spent on neonatal screening cost $24 489. 8 Chest Clinic registered nurses also conducted the relative and health care worker screening at a cost of $14 913. 8 Neonatologists and paediatricians reviewed the neonates at the screening and medical review clinics at a cost of $19 059. 9 Respiratory physicians interviewed and counselled the families of exposed neonates at the initial screening clinics at a cost of $9148. 9 The estimated 910 km travelled for screening home visits and medication delivery cost approximately $682.
Nurses' time spent conducting home visits cost an additional $971. 8 A clinical nurse consultant was appointed to coordinate the investigation over 23 weeks at a cost of $40 970. 8 Screening tests conducted included chest X-rays (220 performed for a total of $10 373), TSTs (487 performed for $1406), IGRAs (10 performed for $500) and sputum smears/cultures (two contacts with three specimens each for $171). 12 The 66 neonates commenced on prophylaxis received a total of 4425 isoniazid treatment days. At an average dose of 50 mg/day the isoniazid solution cost $167, with no additional cost passed onto the families. Manufacturing and dispensing the isoniazid solution took the hospital pharmacists approximately 69 hours, at a cost of $2491. 10 Additional costs included consumables ($1034), parking for families ($1826) and postage for letters sent to families and health care providers (approximately $230).
There are few neonatal nosocomial TB exposure investigations in the published literature, and little evidence on their cost. 2, 5, [13] [14] [15] [16] We estimate the total cost to the hospital of this screening investigation was $128 430. This may underestimate the true cost as some items could not be quantified, including the cost of screening the 15 neonates and their relatives who attended other facilities for screening, the cost to families of travel to the clinics and pharmacy, and the investigation hotline. The time spent by hospital executives, the media unit, the NSW Ministry of Health and Public Health Unit staff is also not included in this estimate.
Indirect costs that are difficult to quantify include the cost of a parent's time away from work and usual duties. The opportunity cost to other departments of scarce health care resources including health care worker time, clinic space and tests used for the investigation is significant but difficult to quantify. The potentially substantial costs of screening investigations are not always included within health service budgets. This episode highlights the importance of including funds for screening within the public health or prevention components of budgets to accommodate such events.
Intangible costs including the anxiety and stress caused to families from the potential infection of their neonate, as well as to exposed health care workers and relatives, are considerable but not readily expressed in dollar terms.
Conclusion
There is a paucity of evidence around neonatal nosocomial TB exposure events, making it difficult to plan an appropriate response. In the absence of information it is difficult to justify not taking a precautionary approach when neonates are involved, but alternative approaches could be considered. Rather than screening all contacts as in this investigation, after careful risk assessment screening could initially be restricted to those with the highest exposure and extended to those at lower risk only if cases are detected. If no evidence of transmission was detected in the most highly-exposed contacts, further unnecessary screening of contacts at lower risk would be prevented, resulting in potential cost savings.
No evidence of transmission was detected in this and previous similar investigations; the risk of nosocomial transmission in the NICU setting appears to be low. [2] [3] [4] [5] [6] [7] [13] [14] [15] [16] [17] This may add confidence that a staged approach for future TB screening activities in neonatal settings can be a safe and cost-effective alternative to initially screening all potentially exposed neonates.
